EasySep™ Human Neutrophil Isolation Kit

14-Minute cell isolation using immunomagnetic negative selection

New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

EasySep™ Human Neutrophil Isolation Kit

14-Minute cell isolation using immunomagnetic negative selection

From: 1,164 USD
Catalog #
17957_C
14-Minute cell isolation using immunomagnetic negative selection

Product Advantages


  • Fast, easy-to-use and column-free

  • Up to 99% purity

  • Untouched, viable cells

What's Included

  • EasySep™ Human Neutrophil Isolation Kit (Catalog #17957)
    • EasySep™ Human Neutrophil Isolation Cocktail, 1 mL
    • EasySep™ Dextran RapidSpheres™, 1 mL
  • RoboSep™ Human Neutrophil Isolation Kit with Filter Tips (Catalog #17957RF)
    • EasySep™ Human Neutrophil Isolation Cocktail, 1 mL
    • EasySep™ Dextran RapidSpheres™, 1 mL
    • RoboSep™ Buffer (Catalog #20104)
    • RoboSep™ Filter Tips (Catalog #20125)
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

Overview

The EasySep™ Human Neutrophil Isolation Kit is designed to isolate neutrophils from a polymorphonuclear cell-rich fraction of peripheral blood by negative selection. Unwanted cells are targeted for removal with Tetrameric Antibody Complexes recognizing non-neutrophils and magnetic particles. Labeled cells are separated using an EasySep™ magnet without the use of columns. Desired cells are poured off into a new tube. The isolation kit is compatible with cells prepared using HetaSep™ (Catalog #07906) sedimentation or red blood cell lysis.

This product replaces the EasySep™ Human Neutrophil Enrichment Kit (Catalog #19257), for even faster cell isolations.
Magnet Compatibility
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
• EasyPlate™ EasySep™ Magnet (Catalog #18102)
• RoboSep™-S (Catalog #21000)
Subtype
Cell Isolation Kits
Cell Type
Granulocytes and Subsets
Species
Human
Sample Source
PMNC, Whole Blood
Selection Method
Negative
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Immunology

Data Figures

Figure 1. Typical EasySep™ Human Neutrophil Isolation Profile

Starting with whole blood prepared using HetaSep™ or Lymphoprep™ with RBC lysis, the neutrophil content (CD45+CD16+CD66b+) of the isolated fraction typically ranges from 98.7 ± 0.9% (mean ± SD). In the above example, the purities of the start and final isolated fractions are 52.0% and 99.0%, respectively.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
17957
Lot #
All
Language
English
Catalog #
17957RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17957
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17957
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17957
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17957RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17957RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17957RF
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (1)

Novel NCF2 Mutation Causing Chronic Granulomatous Disease. I. L. Roth et al. Journal of clinical immunology 2020 oct

Abstract

Chronic granulomatous disease (CGD) is a rare primary immunodeficiency disorder caused by defects in the NADPH oxidase complex. Mutations in NCF2 encoding the cytosolic factor p67phox result in autosomal recessive CGD. We describe three patients with a novel c.855G{\textgreater}C NCF2 mutation presenting with diverse clinical phenotype. Two siblings were heterozygous for the novel mutation and for a previously described exon 8-9 duplication, while a third unrelated patient was homozygous for the novel mutation. Mutation pathogenicity was confirmed by abnormal DHR123 assay and absent p67phox production and by sequencing of cDNA which showed abnormal RNA splicing. Clinically, the homozygous patient presented with suspected early onset interstitial lung disease and NCF2 mutation was found on genetic testing performed in search for surfactant-related defects. The two siblings also had variable presentation with one having history of severe pneumonia, lymphadenitis, and recurrent skin abscesses and the other presenting in his 30s with discoid lupus erythematosus and without significant infectious history. We therefore identified a novel pathogenic NCF2 mutation causing diverse and unusual clinical phenotype.

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.